login
login

Europe Daily Bulletin No. 9284

12 October 2006
Contents Publication in full By article 32 / 43
ECONOMIC INTERPENETRATION / (eu) health

The British company GLAXOSMITHKLINE will be taking over the US CNS laboratory (turnover of $113bn during last tax year), specialised in non-prescription treatments, for $566 million. GLAXOSMITHKLINE will therefore be in a stronger position in the non-prescription medicines market, which represents 14% of its turnover.

Contents

A LOOK BEHIND THE NEWS
THE DAY IN POLITICS
GENERAL NEWS
ECONOMIC INTERPENETRATION
SUPPLEMENT